个人中心 - 老虎社区

miyakos

IP属地：未知

帖子 · 87帖子 · 87
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- miyakosmiyakos
  ·2021-09-14
  Latest
  非常抱歉，此主贴已删除
  1,954 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-13
  Latest
  非常抱歉，此主贴已删除
  1,914 1
  2
  分享
  举报
- miyakosmiyakos
  ·2021-09-09
  Latest
  非常抱歉，此主贴已删除
  1,950 评论
  5
  分享
  举报
- miyakosmiyakos
  ·2021-09-08
  Latest
  非常抱歉，此主贴已删除
  1,771 4
  6
  分享
  举报
- miyakosmiyakos
  ·2021-09-07
  Latest
  非常抱歉，此主贴已删除
  1,672 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-06
  Latest
  This Could Be Novavax's Ace in the Hole<blockquote>这可能是Novavax的王牌</blockquote>
  Hint: It's not the company's COVID-19 vaccine. Key Points Novavax put its flu vaccine program on t
  This Could Be Novavax's Ace in the Hole<blockquote>这可能是Novavax的王牌</blockquote>
  1,218 评论
  3
  分享
  举报
- miyakosmiyakos
  ·2021-09-05
  Latest
  非常抱歉，此主贴已删除
  2,404 1
  7
  分享
  举报
- miyakosmiyakos
  ·2021-09-02
  Yeah
  非常抱歉，此主贴已删除
  2,621 评论
  4
  分享
  举报
- miyakosmiyakos
  ·2021-09-01
  Yes
  非常抱歉，此主贴已删除
  2,022 评论
  1
  分享
  举报
- miyakosmiyakos
  ·2021-08-31
  Latest
  非常抱歉，此主贴已删除
  1,688 评论
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4088416347172780","uuid":"4088416347172780","gmtCreate":1625317032982,"gmtModify":1625317032982,"name":"miyakos","pinyin":"miyakos","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":5,"tweetSize":87,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":882081815,"gmtCreate":1631631128137,"gmtModify":1631890297396,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/882081815","repostId":"1185574136","repostType":4,"isVote":1,"tweetType":1,"viewCount":1954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888750587,"gmtCreate":1631532248849,"gmtModify":1631890297413,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/888750587","repostId":"1133730816","repostType":4,"isVote":1,"tweetType":1,"viewCount":1914,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883019705,"gmtCreate":1631188037807,"gmtModify":1631890297422,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883019705","repostId":"2166312201","repostType":4,"isVote":1,"tweetType":1,"viewCount":1950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889316628,"gmtCreate":1631109353464,"gmtModify":1631890297432,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/889316628","repostId":"1131499618","repostType":4,"isVote":1,"tweetType":1,"viewCount":1771,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880987948,"gmtCreate":1631009921884,"gmtModify":1631890297446,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/880987948","repostId":"2165330144","repostType":4,"isVote":1,"tweetType":1,"viewCount":1672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817838648,"gmtCreate":1630929051884,"gmtModify":1631890297459,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/817838648","repostId":"1121589231","repostType":4,"repost":{"id":"1121589231","kind":"news","pubTimestamp":1630927585,"share":"https://www.laohu8.com/m/news/1121589231?lang=zh_CN&edition=full","pubTime":"2021-09-06 19:26","market":"us","language":"en","title":"This Could Be Novavax's Ace in the Hole<blockquote>这可能是Novavax的王牌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1121589231","media":"Motley Fool","summary":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on t","content":"<p>  <b>Hint: It's not the company's COVID-19 vaccine.</b>  <b>Key Points</b></p><p><blockquote><b>提示：这不是该公司的新冠肺炎疫苗。</b><b>要点</b></blockquote></p><p> <ul>  <li>Novavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.</li>  <li>The company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.</li>  <li>Novavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.</li> </ul> <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.</p><p><blockquote><ul><li>Novavax在2020年将重点转向COVID-19后，将其流感疫苗计划置于次要位置。</li><li>该公司已经报告了其实验性纳米流感疫苗后期研究的积极结果。</li><li>Novavax正在推进新冠肺炎/流感组合的测试，这可能会使该公司有别于其他疫苗制造商。</li></ul><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>有怀疑者。一些人指出了该公司的失败历史。其呼吸道合胞病毒(RSV)候选疫苗ResVax经历了两次临床挫折，并三次推迟了申请COVID-19候选疫苗NVX-CoV2373紧急使用授权(EUA)的预期时间表。</blockquote></p><p> However, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.</p><p><blockquote>然而，这只生物技术股票的未来可能比许多批评者想象的更光明。Novavax应在几周内在英国申请NVX-CoV2373的EUA，随后很快在欧盟和其他国家提交申请。</blockquote></p><p> Its COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.</p><p><blockquote>Novavax的COVID-19疫苗虽然姗姗来迟，但仍可能取得商业成功。但该公司的管道中还有另一个候选人，可能是其王牌。</blockquote></p><p> <b>A hot candidate on the back burner</b></p><p><blockquote><b>被搁置的热门候选人</b></blockquote></p><p> With all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.</p><p><blockquote>随着NVX-CoV2373的喧嚣，人们很容易忘记，就在不久前，投资者还对Novavax开发的另一种实验性疫苗感到兴奋。该公司在2018年初报告了1/2期研究的令人鼓舞的结果后，对候选流感疫苗NanoFlu寄予厚望。</blockquote></p><p> Novavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.</p><p><blockquote>Novavax于2018年9月将NanoFlu推进到老年人的2期测试。它在2019年1月报道了该临床试验的更多好消息。</blockquote></p><p> That set the stage for NanoFlu's phase 3 study -- a head-to-head comparison with<b>Sanofi</b>'s&nbsp;approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.</p><p><blockquote>这为NanoFlu的3期研究奠定了基础——与<b>赛诺菲</b>批准的流感疫苗FluZone四价。该研究于2019年10月开始。次年3月，Novavax宣布了积极的结果，NanoFlu在该研究的主要和次要终点上明显击败了FluZone。</blockquote></p><p> The company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.</p><p><blockquote>该公司似乎准备迅速申请批准NanoFlu。然而，随着Novavax推进其COVID-19疫苗开发，其流感疫苗计划被推到了次要位置。</blockquote></p><p> <b>A compelling combo</b></p><p><blockquote><b>引人注目的组合</b></blockquote></p><p> It made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.</p><p><blockquote>Novavax选择专注于其COVID-19项目是有道理的。这个机会太大了，不容忽视，Novavax的资源只能分散到这里。随着美国政府向该公司投入16亿美元开发NVX-CoV2373，优先事项的转变是显而易见的。</blockquote></p><p> However, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.</p><p><blockquote>然而，Novavax当然没有忘记NanoFlu。该公司认为，以NVX-CoV2373和NanoFlu为特色的新冠肺炎/流感联合疫苗可能会成为赢家。</blockquote></p><p> Novavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.</p><p><blockquote>Novavax已经宣布了评估NanoFlu/NVX-CoV2373组合疫苗的有希望的临床前数据。该公司计划今年晚些时候在澳大利亚启动一项一期研究，以评估该实验性组合。</blockquote></p><p> NanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.<b>Pfizer</b>&nbsp;and<b>BioNTech</b>&nbsp;are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.<b>Moderna</b>only recently began early-stage clinical studies of its experimental flu vaccine.</p><p><blockquote>NanoFlu确实可能是Novavax区别于其他COVID-19疫苗制造商的关键。<b>辉瑞</b>和<b>BioNTech</b>正在研究一种候选流感疫苗，但尚未进入临床测试。<b>现代</b>直到最近才开始对其实验性流感疫苗进行早期临床研究。</blockquote></p><p> Meanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.</p><p><blockquote>与此同时，Novavax已经证明了NanoFlu的安全性和有效性。它还已经在推进新冠肺炎/流感组合疫苗的临床测试，这是竞争对手尚未做到的。如果未来需要新冠肺炎的年度加强剂，新冠肺炎/流感联合疫苗可以提供一个令人信服的价值主张。Novavax似乎是这方面的领导者。</blockquote></p><p> <b>A good bet?</b></p><p><blockquote><b>一个好赌注？</b></blockquote></p><p> I understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.</p><p><blockquote>考虑到Novavax过去的业绩记录，我理解为什么有些人可能会对该公司持怀疑态度。然而，该公司比以往任何时候都更有能力取得成功。Novavax已经报告了英国和美国后期研究中NVX-CoV2373的积极结果。现在的主要障碍是完成疫苗的监管备案。</blockquote></p><p> Assuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.</p><p><blockquote>假设Novavax赢得EUA，它应该会赚很多钱。该公司最近与欧盟签署了一项协议，最初供应1亿剂NVX-CoV2373，并额外供应1亿剂。Novavax可能很快就会有充足的财政资源来资助其新冠肺炎/流感组合疫苗项目。</blockquote></p><p> It's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.</p><p><blockquote>分析师看好疫苗股票对我来说一点也不奇怪。凭借NVX-CoV2373和NanoFlu作为王牌的诱人前景，Novavax似乎是一个不错的选择。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Novavax's Ace in the Hole<blockquote>这可能是Novavax的王牌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Novavax's Ace in the Hole<blockquote>这可能是Novavax的王牌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-06 19:26</span>\n</p>\n</h4>\n</header>\n<article>\n<p>  <b>Hint: It's not the company's COVID-19 vaccine.</b>  <b>Key Points</b></p><p><blockquote><b>提示：这不是该公司的新冠肺炎疫苗。</b><b>要点</b></blockquote></p><p> <ul>  <li>Novavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.</li>  <li>The company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.</li>  <li>Novavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.</li> </ul> <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.</p><p><blockquote><ul><li>Novavax在2020年将重点转向COVID-19后，将其流感疫苗计划置于次要位置。</li><li>该公司已经报告了其实验性纳米流感疫苗后期研究的积极结果。</li><li>Novavax正在推进新冠肺炎/流感组合的测试，这可能会使该公司有别于其他疫苗制造商。</li></ul><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>有怀疑者。一些人指出了该公司的失败历史。其呼吸道合胞病毒(RSV)候选疫苗ResVax经历了两次临床挫折，并三次推迟了申请COVID-19候选疫苗NVX-CoV2373紧急使用授权(EUA)的预期时间表。</blockquote></p><p> However, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.</p><p><blockquote>然而，这只生物技术股票的未来可能比许多批评者想象的更光明。Novavax应在几周内在英国申请NVX-CoV2373的EUA，随后很快在欧盟和其他国家提交申请。</blockquote></p><p> Its COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.</p><p><blockquote>Novavax的COVID-19疫苗虽然姗姗来迟，但仍可能取得商业成功。但该公司的管道中还有另一个候选人，可能是其王牌。</blockquote></p><p> <b>A hot candidate on the back burner</b></p><p><blockquote><b>被搁置的热门候选人</b></blockquote></p><p> With all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.</p><p><blockquote>随着NVX-CoV2373的喧嚣，人们很容易忘记，就在不久前，投资者还对Novavax开发的另一种实验性疫苗感到兴奋。该公司在2018年初报告了1/2期研究的令人鼓舞的结果后，对候选流感疫苗NanoFlu寄予厚望。</blockquote></p><p> Novavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.</p><p><blockquote>Novavax于2018年9月将NanoFlu推进到老年人的2期测试。它在2019年1月报道了该临床试验的更多好消息。</blockquote></p><p> That set the stage for NanoFlu's phase 3 study -- a head-to-head comparison with<b>Sanofi</b>'s&nbsp;approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.</p><p><blockquote>这为NanoFlu的3期研究奠定了基础——与<b>赛诺菲</b>批准的流感疫苗FluZone四价。该研究于2019年10月开始。次年3月，Novavax宣布了积极的结果，NanoFlu在该研究的主要和次要终点上明显击败了FluZone。</blockquote></p><p> The company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.</p><p><blockquote>该公司似乎准备迅速申请批准NanoFlu。然而，随着Novavax推进其COVID-19疫苗开发，其流感疫苗计划被推到了次要位置。</blockquote></p><p> <b>A compelling combo</b></p><p><blockquote><b>引人注目的组合</b></blockquote></p><p> It made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.</p><p><blockquote>Novavax选择专注于其COVID-19项目是有道理的。这个机会太大了，不容忽视，Novavax的资源只能分散到这里。随着美国政府向该公司投入16亿美元开发NVX-CoV2373，优先事项的转变是显而易见的。</blockquote></p><p> However, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.</p><p><blockquote>然而，Novavax当然没有忘记NanoFlu。该公司认为，以NVX-CoV2373和NanoFlu为特色的新冠肺炎/流感联合疫苗可能会成为赢家。</blockquote></p><p> Novavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.</p><p><blockquote>Novavax已经宣布了评估NanoFlu/NVX-CoV2373组合疫苗的有希望的临床前数据。该公司计划今年晚些时候在澳大利亚启动一项一期研究，以评估该实验性组合。</blockquote></p><p> NanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.<b>Pfizer</b>&nbsp;and<b>BioNTech</b>&nbsp;are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.<b>Moderna</b>only recently began early-stage clinical studies of its experimental flu vaccine.</p><p><blockquote>NanoFlu确实可能是Novavax区别于其他COVID-19疫苗制造商的关键。<b>辉瑞</b>和<b>BioNTech</b>正在研究一种候选流感疫苗，但尚未进入临床测试。<b>现代</b>直到最近才开始对其实验性流感疫苗进行早期临床研究。</blockquote></p><p> Meanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.</p><p><blockquote>与此同时，Novavax已经证明了NanoFlu的安全性和有效性。它还已经在推进新冠肺炎/流感组合疫苗的临床测试，这是竞争对手尚未做到的。如果未来需要新冠肺炎的年度加强剂，新冠肺炎/流感联合疫苗可以提供一个令人信服的价值主张。Novavax似乎是这方面的领导者。</blockquote></p><p> <b>A good bet?</b></p><p><blockquote><b>一个好赌注？</b></blockquote></p><p> I understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.</p><p><blockquote>考虑到Novavax过去的业绩记录，我理解为什么有些人可能会对该公司持怀疑态度。然而，该公司比以往任何时候都更有能力取得成功。Novavax已经报告了英国和美国后期研究中NVX-CoV2373的积极结果。现在的主要障碍是完成疫苗的监管备案。</blockquote></p><p> Assuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.</p><p><blockquote>假设Novavax赢得EUA，它应该会赚很多钱。该公司最近与欧盟签署了一项协议，最初供应1亿剂NVX-CoV2373，并额外供应1亿剂。Novavax可能很快就会有充足的财政资源来资助其新冠肺炎/流感组合疫苗项目。</blockquote></p><p> It's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.</p><p><blockquote>分析师看好疫苗股票对我来说一点也不奇怪。凭借NVX-CoV2373和NanoFlu作为王牌的诱人前景，Novavax似乎是一个不错的选择。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121589231","content_text":"Hint: It's not the company's COVID-19 vaccine.\n\nKey Points\n\nNovavax put its flu vaccine program on the back burner after shifting to focus on COVID-19 in 2020.\nThe company has already reported positive results from a late-stage study of its experimental NanoFlu flu vaccine.\nNovavax is moving forward with testing a COVID-19/flu combo that could potentially set the company apart from other vaccine makers.\n\nNovavax has its skeptics. Some point to the company's history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it haspushed back its anticipated timelinefor filing for Emergency Use Authorizations (EUAs) of its COVID-19 vaccine candidate NVX-CoV2373 three times.\nHowever, the future for this biotech stock could be brighter than many critics think. Novavax should file for EUA in the U.K. for NVX-CoV2373 within weeks, followed quickly by filings in the European Union and other countries.\nIts COVID-19 vaccine, while somewhat late to the party, could still be a commercial success for Novavax. But there's also another candidate in the company's pipeline that just might be its ace in the hole.\nA hot candidate on the back burner\nWith all of the hubbub over NVX-CoV2373, it's easy to forget that it wasn't all that long ago that investors were excited about another experimental vaccine developed by Novavax. The company had high hopes for flu vaccine candidate NanoFlu after reporting encouraging results in early 2018 from a phase 1/2 study.\nNovavax advanced NanoFlu into phase 2 testing in older adults in September 2018. It reported more good news from that clinical trial in January 2019.\nThat set the stage for NanoFlu's phase 3 study -- a head-to-head comparison withSanofi's approved flu vaccine FluZone Quadrivalent. The study began in October 2019. The following March, Novavax announced positive results, with NanoFlu clearly beating FluZone in the study's primary and secondary endpoints.\nThe company seemed to be set to move quickly to file for approval of NanoFlu. However, its flu vaccine program was pushed to the back burner with Novavax moving forward with its COVID-19 vaccine development.\nA compelling combo\nIt made sense that Novavax chose to focus on its COVID-19 program. The opportunity was too great to ignore, and Novavax's resources could only be spread out so far. And with the U.S. government throwing $1.6 billion the company's way to develop NVX-CoV2373, a shift in priorities was a no-brainer.\nHowever, Novavax certainly hasn't forgotten about NanoFlu. The company thinks that a combination COVID-19/flu vaccine featuring NVX-CoV2373 and NanoFlu could be a winner.\nNovavax has already announced promising preclinical data evaluating a NanoFlu/NVX-CoV2373 combination vaccine. It plans to initiate a phase 1 study in Australia later this year to evaluate the experimental combo.\nNanoFlu truly could be the key to Novavax setting itself apart from other COVID-19 vaccine makers.Pfizer andBioNTech are working on a flu vaccine candidate, but it hasn't advanced into clinical testing yet.Modernaonly recently began early-stage clinical studies of its experimental flu vaccine.\nMeanwhile, Novavax has already demonstrated NanoFlu's safety and efficacy. It's also already moving ahead with clinical testing of a COVID-19/flu combo vaccine, something that rivals haven't done yet. Should annual boosters for COVID-19 be needed in the future, a combo COVID-19/flu vaccine could provide a compelling value proposition. Novavax appears to be the leader on this front.\nA good bet?\nI understand why some might be skeptical about Novavax considering the company's past track record. However, the company is in a better position than ever to succeed. Novavax has already reported positive results for NVX-CoV2373 from late-stage studies in the U.K. and the U.S. The primary hurdle now is to complete the regulatory filings for the vaccine.\nAssuming Novavax wins EUAs, it should be set to make a boatload of money. The company recently signed a deal with the European Union to supply 100 million doses initially and up to 100 million additional doses of NVX-CoV2373. Novavax could soon have ample financial resources to fund its COVID-19/flu combo vaccine program.\nIt's not surprising at all to me that analysts are bullish about thevaccine stock. With the attractive prospects for NVX-CoV2373 and NanoFlu as its ace in the hole, Novavax appears to be a pretty good bet.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814533960,"gmtCreate":1630840174950,"gmtModify":1631890297470,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/814533960","repostId":"2164803577","repostType":4,"isVote":1,"tweetType":1,"viewCount":2404,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812568610,"gmtCreate":1630595120830,"gmtModify":1631890297482,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812568610","repostId":"2164821842","repostType":4,"isVote":1,"tweetType":1,"viewCount":2621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816689882,"gmtCreate":1630495932646,"gmtModify":1631890297494,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816689882","repostId":"2164894947","repostType":4,"isVote":1,"tweetType":1,"viewCount":2022,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818206299,"gmtCreate":1630409504711,"gmtModify":1631890297508,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088416347172780","authorIdStr":"4088416347172780"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818206299","repostId":"2163859671","repostType":4,"isVote":1,"tweetType":1,"viewCount":1688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}